Publications by authors named "Gulsum Altiparmak-Ulbegi"

This study used 80% ammonium sulphate fractional precipitation, followed by affinity chromatography to purify a new lectin (AVL) from the crude extract of the mushroom. The purification procedure achieved a 20% yield, a specific activity of 5120 HU/mg protein, and a 16-fold increase in purity. SDS-PAGE analysis showed a single band of 45 kDa.

View Article and Find Full Text PDF

Breast cancer (BC) is the most prevalent cancer type in the world, with increasing incidence rates. Drug resistance is a notable factor that limits the effectiveness of BC therapy. Paclitaxel (PTX), a chemotherapeutic agent belonging to the taxane class, is commonly used in BC; however, its efficacy is often compromised by drug resistance, which is primarily attributed to genetic alterations.

View Article and Find Full Text PDF

In search of selective cytotoxic compounds from species as potential leads for the treatment of various cancer diseases, a bioactivity-guided isolation study was performed on the roots of M. Bieb. COLO 205 (colon), K-562 (leukemia), and MCF-7 (breast) cancer cell lines were used to monitor the cytotoxic activity of column fractions and determine the IC value of the active compounds.

View Article and Find Full Text PDF

Ancient physicians frequently used the resin of species to treat cancer. Today, some folkloric recipes used for cancer treatment also contain the resin of species. The dichloromethane extract of the roots of exhibited cytotoxic activities against COLO 205 (colon), K-562 (lymphoblast), and MCF-7 (breast) cancer cell lines (IC = 52 µg/mL, 72 µg/mL, and 20 µg/mL, respectively).

View Article and Find Full Text PDF

This study is the first chemical investigation of Ferula mervynii M. Sağıroğlu & H. Duman, an endemic species to Eastern Anatolia.

View Article and Find Full Text PDF

In anticancer therapy, the effectiveness of therapeutics is limited by mutations causing drug resistance. mutations are the only determinant for cetuximab resistance in patients with colorectal cancer (CRC). However, cetuximab treatment has not been fully successful in the majority of patients with wild-type (WT) .

View Article and Find Full Text PDF